Iran breaks US monopoly in prostate cancer drug

TEHRAN, Feb. 03 (MNA) – Iranian researchers in Polymer and Petrochemical Institute could set up the production line of prostate cancer drug which was exclusively confined to the US.

The head of Iran’s Polymer and Petrochemical Institute Mehdi Nekoumanesh, while announcing the unveiling process of ‘leuprolide acetate’, said it is a one-month injecting drug for prostate cancer which is the same as the Amrican drug with the same application.

In addition to prostate cancer, Nekoumanesh added, the drug is also used to treat diseases related to uterine fibroids and infertility in women.

Stating that the drug which was exclusively produced in the US, cost about 400 Euros, Nekoumanesh said, “Now we can export the drug to other countries such as Yemen and Syria, in addition to providing the domestic needs.”

Iran is the world’s second producer of this type of medication, he underlined, saying that the newly-produced drug in Iran is equivalent to the American version.

By Mehr News Agency

The Iran Project is not responsible for the content of quoted articles.